Annovera generic
Annovera is a contraceptive drug owned by Therapeuticsmd Inc., featuring Ethinyl Estradiol and Segesterone Acetate as its active ingredients. It was authorized for market use on August 10, 2018. The drug is available in the form of a vaginal ring.
When will Annovera generic be available?
The generics of Annovera are expected to be released after June 21, 2039, following the expiration of the last-held patent. This is due to the patent protection granted to the drug, which blocks the production of generic versions until the patent rights are in place. Drug patent challenges can be filed against Annovera starting from August 10, 2022.
Annovera uses
Annovera is primarily used as a method of contraception. It involves a vaginal system that's inserted for up to thirteen 21/7-day (in/out) cycles. The efficacy of the drug requires that the system does not remain out of the vagina for more than two cumulative hours in any such cycle without using alternative contraception. The vaginal system contains 103 mg of Segesterone Acetate and 17.4 mg Ethinyl Estradiol, which work together to prevent pregnancy.
Annovera patent expiration
Annovera holds a total of 7 drug patents, none of which have expired as yet. These patents relate to the system and method of providing birth control. The last known patent is due to expire on June 21, 2039. After this date, Annovera generic versions can potentially enter the market. Below are the details of the patent: